INPP5D and Alzheimer disease: Furthermore, studies using the 5xFAD mouse model show that INPP5D/SHIP1 is upregulated as Aβ pathology progresses and that INPP5D/SHIP1 haploinsufficiency normalizes AD‐related neuropathology and behavioral deficits, which suggests that inhibition of INPP5D/SHIP1 early in AD would increase TREM2 signaling and microglial protective functions, resulting in reduced rate of disease progression and cognitive decline in AD.112